Cytosorbents (CTSO) Stock Forecast: StockMap's 2-Week Call
CTSO stock forecast: StockMap's model leans Underperform on Cytosorbents for the two weeks after the Nov 19 close, toward CTSO trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on CTSO since Aug 21; by chance, a call on the same dates was right 59% of the time.
Cytosorbents last closed at $5.13, -7.90% on the session.
Against the IVW growth benchmark the position is -5.57% over the forecast window.
Cytosorbents' market cap is $16.15M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -48 (too close to call).
Where CTSO sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 1 bullish and 14 bearish.
Agreement across those insights is 93%.
49 daily calls for CTSO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
Cytosorbents is classified under Health Care / Health Care Equipment & Supplies.
StockMap tracks Cytosorbents as the 122nd largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.
Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.
On that composite Cytosorbents ranks 124th of 141 in the group, against a group median of -0.18.